| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,300 | 5,650 | 15:53 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 33,000 | 33 | |||
| 20,000 | 83 | |||
| 16,000 | 32 | |||
| 15,000 | 15 | |||
| 11,500 | 100 | |||
| 11,000 | 500 | |||
| 10,000 | 41 | |||
| 9,500 | 275 | |||
| 6,350 | 500 | |||
| 5,600 | 855 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 855 | 5,300 | |||
| 300 | 4,900 | |||
| 700 | 4,740 | |||
| 110 | 4,700 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 3.026 | 0,804 | 2.434 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 09.09.2026 | 10:30:21 | 5,600 | 99 |
| Tagesumsatz Xetra | 0,000 0,00 % | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | 4basebio Plc - 4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine | 565 | PR Newswire | 4basebio Plc - 4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine
PR Newswire
LONDON, United Kingdom, September 07
4basebio... ► Artikel lesen | |
| 27.08. | Genezen to Offer Access to 4basebio Synthetic DNA Platform for Viral Vectors | 22 | Contract Pharma | ||
| 26.08. | 4basebio shares jump on new marketing tie-up with US-based Genezen | 9 | Alliance News | ||
| 26.08. | 4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing | 355 | GlobeNewswire (Europe) | Commercial collaboration combines 4basebio's synthetic DNA technology with Genezen's viral vector development and manufacturing expertise to support gene therapy programs from early development through... ► Artikel lesen | |
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| 26.08. | 4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing | 268 | PR Newswire | Commercial collaboration combines 4basebio's synthetic DNA technology with Genezen's viral vector development and manufacturing expertise to support gene therapy programs from early development... ► Artikel lesen |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 12:15 | EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Group (EN) | EQS Voting Rights Announcement: Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| 12:15 | EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Group (EN) | EQS Voting Rights Announcement: Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| 10:35 | Rakovina Therapeutics beruft Professorin Petra Hamerlik in den Verwaltungsrat | IR-WORLD | Inhaberin des Lehrstuhls für Translationale Neuroonkologie an der University of Manchester und zuvor Mitglied des wissenschaftlichen Beirats
des Unternehmens wurde auf der Hauptversammlung 2026... ► Artikel lesen | |
| 08:26 | Faron Pharmaceuticals: Faron Announces R&D Day | ACCESS Newswire | Faron announces R&D Day to be held on 8 October 2026 TURKU, FI / ACCESS Newswire / September 10, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a global, clinical-stage biopharmaceutical company... ► Artikel lesen | |
| 13:26 | Resverlogix Corp.: Resverlogix Announces Publication of Scientific Journal Articles Relating to Apabetalone's Prevention of Heart Failure | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 10, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces the publication of two new scientific journal articles on mechanisms... ► Artikel lesen |